Compare Abbott Laboratories (ABT) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Upstart Holdings Inc — how do they compare? Abbott Laboratories trades at $95.4 (market cap $166.94B), while Upstart Holdings Inc trades at $31.63 (market cap $3.16B). The key difference: Abbott Laboratories is far larger — about 52.8× Upstart Holdings Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Upstart Holdings Inc pays none. Which is the better fit depends on your goals.
| ABT | UPST | |
|---|---|---|
Market Cap | $166.94B | $3.16B |
Sector | Health | Financials |
52-Week High | $136.62 | $84.13 |
52-Week Low | $82.57 | $24.22 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Upstart trades at $33.06, down 4.95% today, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported $1.02B revenue in 2025 with net income of $53.60M, marking a return to profitability after previous losses. Recent news highlights AI lending growth and a $600M funding deal with Neuberger (Business Wire, June 24, 2026).
Outlook is cautiously optimistic with a consensus price target of $43.00 (45% buy ratings), but risks include volatile cash flows, high debt-to-asset ratio of 61.48%, and execution challenges in expanding auto/home lending products. The stock offers upside if AI-driven originations sustain growth, yet remains sensitive to funding and macroeconomic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
